Talent development and succession planning are simultaneously the most important things a pharma CEO can invest in and among the easiest to deprioritize in the face of near-term operational demands. The argument for CEO investment in talent is simple: in a knowledge-intensive industry like pharmaceuticals, the quality of the leadership team is the primary determinant of whether a company can discover, develop, and commercialize medicines successfully over the long term.
Yet talent development and succession planning also represent functions where the CEO’s direct involvement should be deliberately structured rather than omnipresent. The chief human resources officer (CHRO) and the broader HR function exist to design and operate the talent systems that develop leaders at scale. The CEO’s role is to set the standards, model the behaviors, hold the organization accountable for talent performance, and personally invest in the development of a small number of mission-critical leaders.
The CEO’s Core Talent Responsibilities
Before building a delegation framework, it is useful to be explicit about what the pharma CEO should personally own in talent development and succession.
Owning the talent standard. The CEO defines what excellent leadership looks like in the organization: the values, behaviors, and capabilities that leaders at every level are expected to demonstrate. This standard cannot be delegated because it reflects the CEO’s vision for the kind of organization being built.
Personally developing the direct reports. The CEO should be the primary developer of the executive team. This means regular one-on-one coaching conversations, honest performance feedback, intentional development assignments, and active investment in each executive’s growth. The CHRO can support this work with frameworks and tools, but the actual developmental relationship is between the CEO and each direct report.
Succession planning for the CEO role and direct report positions. The board and the CEO share accountability for CEO succession. The CEO should own the process of identifying and developing internal candidates and should be actively engaged in board conversations about succession. For direct report positions, the CEO leads succession planning with CHRO support.
Modeling talent development as a priority. How the CEO spends time sends a powerful signal about organizational values. When CEOs consistently invest time in talent review sessions, development conversations, and recognition of strong leaders at all levels, it signals that talent development is a genuine priority rather than an HR program.
What the CEO Should Delegate
Most of the operational machinery of talent development should be owned by the CHRO and HR organization. The CEO should delegate:
Design and operation of talent review processes (annual talent assessments, nine-box evaluations, potential ratings) to the CHRO, with the CEO participating in the most senior talent discussions.
Development program design and delivery: the company’s leadership development programs, manager effectiveness training, mentoring structures, and high-potential rotational programs are HR-owned functions. The CEO may occasionally participate as a faculty member or sponsor, but should not be involved in program design or logistics.
Talent acquisition below the executive team level: recruiting for VP and below positions should be fully delegated to business leaders and HR business partners, with the CEO involved only in hiring for direct report positions.
Performance management system design: the mechanics of how performance is evaluated, how ratings are calibrated, and how feedback is delivered are CHRO-owned functions. The CEO should set the expectations (including the expectation that performance management is taken seriously) but should not be involved in system design.
Compensation benchmarking and structure below the executive level: total rewards strategy is an HR function, with the CEO’s involvement focused on executive compensation decisions (in partnership with the board’s compensation committee).
Building the Talent Governance Calendar
An effective delegation framework for talent development requires a governance calendar that ensures CEO visibility into talent quality and pipeline without requiring continuous involvement in operational HR processes.
A practical talent governance calendar for pharma CEOs includes:
Monthly: Individual development conversations with each direct report (typically embedded in regular one-on-one meetings). These conversations should address progress against development goals, emerging challenges, and upcoming opportunities for growth.
Quarterly: Senior talent review (2 to 3 hours, covering the top 50 to 100 leaders in the organization). The CEO and CHRO review talent assessments, succession pipelines, flight risk concerns, and development actions for the most senior leadership population. This session keeps the CEO connected to the talent bench without reviewing all 5,000 employees personally.
Annual: Organization-wide talent review (CEO reviews the CHRO’s summary of talent health across the organization, including key metrics on leadership pipeline strength, diversity representation, and retention of high-potential talent). This annual review informs strategic planning and resource allocation decisions.
Board talent update: Quarterly or semi-annual update to the board on CEO succession, executive team strength, and organizational leadership pipeline. The CEO and CHRO typically co-present this update.
Succession Planning Framework
Succession planning in pharma requires particular attention because the industry’s technical complexity means that certain leadership roles require very long development timelines. A future chief medical officer or chief scientific officer may need to be identified and developed 10 to 15 years before they are ready for the role.
The CEO’s succession planning responsibilities extend beyond just the CEO role to encompass the entire executive team. A practical framework divides succession planning into three time horizons:
Immediate succession (0 to 12 months): Who can step into each critical role on short notice if an executive departs unexpectedly? These “emergency successors” may not be fully ready for the role but are the best available internal option. Every executive team position should have a named emergency successor.
Near-term succession (1 to 3 years): Who is actively developing toward readiness for each executive role? These leaders should have specific development plans addressing their gaps and should be given stretch assignments that build the capabilities needed for the next level.
Long-term pipeline (3 to 10 years): Which leaders in the organization have the potential to reach the executive team in the future? These leaders should be in high-potential development programs, receiving broad experience across functions and geographies, and assessed regularly for potential.
The CEO should own the immediate and near-term succession planning for direct report positions, with the CHRO owning the long-term pipeline development process and reporting to the CEO on pipeline strength.
Delegating Development Programs Without Losing Visibility
One of the most effective ways pharma CEOs can invest in talent development while delegating the operational work is to serve as a strategic sponsor for key development programs. When the CEO periodically addresses cohorts of high-potential leaders, teaches in leadership development programs, or sponsors specific groups (such as a CEO roundtable for emerging leaders), they create a signal effect that motivates participants and demonstrates personal investment in leadership development without requiring operational program management.
This sponsor role is high-impact and low-operational-burden when structured correctly. The CHRO owns the program design and logistics; the CEO provides targeted, high-quality engagement at strategic moments.
The CHRO Partnership
Effective talent development delegation depends more than almost any other function on the quality of the CEO-CHRO partnership. The CHRO needs to be a strategic talent partner who understands the business deeply enough to advise on organizational design and talent implications of strategic choices, and who has the credibility to challenge the CEO when the organizational culture or people practices are not supporting the strategy.
Pharma CEOs who treat the CHRO as primarily a transactional HR administrator are missing a significant leadership leverage point. The CHRO role, when filled by the right person and supported by the right CEO relationship, is one of the most powerful delegation partnerships available to the CEO.
For context on how pharma CEOs structure broader organizational delegation, the R&D delegation framework provides useful parallels for technical talent development. For companies where talent development intersects with global operations and digital transformation, the digital health delegation guide offers complementary perspectives.
Managing Talent Development in a Science-Intensive Organization
Pharma companies present unique talent development challenges because of the deep scientific expertise required in R&D, medical affairs, and regulatory functions. Scientists and physicians who aspire to leadership roles often need development pathways that balance continued scientific contribution with increasing organizational leadership.
The CEO should ensure that the CHRO and R&D leadership are jointly designing talent development pathways that serve both the organization’s scientific needs and the individual’s growth aspirations. This includes decisions about dual career tracks (scientific versus management), leadership development programs designed for scientific audiences, and succession planning that preserves technical expertise in the leadership pipeline.
Accountability Mechanisms for Talent Development
Talent development delegation works best when the organizational system holds leaders accountable for developing their people. Pharma CEOs should ensure that talent development effectiveness is part of how executive performance is evaluated.
This means including talent development metrics in executive performance reviews: succession pipeline health for key roles, retention rates of high-potential talent, employee engagement scores, and diversity representation at senior levels. When executives know that their performance ratings and compensation are partially determined by the strength of the talent bench they build, delegation of talent development to the executive team is reinforced by a compelling accountability mechanism.
Conclusion
Talent development and succession planning represent a domain where the pharma CEO’s personal investment is both irreplaceable and appropriately bounded. By personally owning the talent standard, the development of direct reports, and senior succession planning, while delegating the operational machinery of talent development to a strong CHRO, pharma CEOs can build the deep leadership pipeline that the industry’s complexity and long time horizons demand. The organizations that consistently produce excellent leadership at every level are those where the CEO has both the personal commitment and the delegation discipline to make talent development a genuine organizational priority.
Related Reading
For further context, explore Delegation Guide for Affordable Housing Nonprofit CEOs and Delegation Guide for Automotive CEO: Brand Management.